Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $4.35M |
| Net Income (Most Recent Fiscal Year) | $-45.53M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 32.86 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1211.30% |
| Net Margin (Trailing 12 Months) | -1418.39% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -96.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.90 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 15.32 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.78 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.88 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.04 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 137.68M |
| Free Float | 128.32M |
| Market Capitalization | $144.57M |
| Average Volume (Last 20 Days) | 0.68M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 74.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |